Current Allergy and Asthma Reports

, Volume 7, Issue 1, pp 41–48 | Cite as

Sulfonamide allergy and cross-reactivity



Concerns about cross-allergenicity between sulfonamide antibiotics and nonantibiotic sulfonamide-containing drugs continue to complicate pharmacotherapy. Several elegant investigations have demonstrated unequivocal lack of interaction between the sulfonamide group and either cellular or humoral immunity. The immunologic determinant of type I immunologic responses to sulfonamide antibiotics is the N1 heterocyclic ring, and nonantibiotic sulfonamides lack this structural feature. Many non-type I hypersensitivity responses to sulfonamide antibiotics are attributable to reactive metabolites that cause either direct cytotoxicity or humoral or cellular responses. Metabolite formation is stereospecific to the N4 amino nitrogen of the sulfonamide antibiotics, a structure not found on any nonantibiotic sulfonamide drugs. Cellular immune responses to sulfonamide antibiotics are responsible for many non-immunoglobulin E-mediated dermatologic reactions; however, the stereospecificity of T-cell response renders cross-reactivity between sulfonamide antibiotics and nonantibiotics highly unlikely. Apparent cross-reactivity responses to sulfonamide-containing drugs likely represent multiple concurrent, rather than linked, drug hypersensitivities.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Tilles S: Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J 2001, 94:817–824.PubMedGoogle Scholar
  2. 2.
    Kucera C, Greenberger P: Adverse drug reactions: treatment and prevention. Hosp Med 1996, 32:11–24.Google Scholar
  3. 3.
    Sullivan TJ, Ong RC, Gilliam LK: Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol 1989, 83:270.CrossRefGoogle Scholar
  4. 4.
    Patterson R, Bello AE, Lefkowith J: Immunologic tolerability profile of celecoxib. Clin Ther 1999, 21:2065–2079.PubMedCrossRefGoogle Scholar
  5. 5.
    Alfirevic A, Stalford AC, Viklar FJ, et al.: Slow acetylator phenotype and genotype in HIV-positive patients with sulfamethoxazole hypersensitivity. Br J Clin Pharmacol 2003, 55:158–165.PubMedCrossRefGoogle Scholar
  6. 6.
    Bukhalo M, Zeitouni NC, Cheney RT: Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. Cutis 2003, 3:235–238.Google Scholar
  7. 7.
    Klinder KP, Harbilas JW, Johns TE: Drug-induced hematologic disorders. In Pharmacotherapy: A Pathophysiologic Approach, edn 5. Edited by Dipiro J, et al., New York: McGraw-Hill; 2002:1783–1795.Google Scholar
  8. 8.
    Kuby J, ed: Hypersensitivity reactions in immunology. In Immunology, edn 3. Philadelphia: W.H. Freeman and Co.; 1997:413–439.Google Scholar
  9. 9.
    Leyva L, Torres MJ, Posadas S, et al.: Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J Allergy Clin Immunol 2000, 105:157–165.PubMedCrossRefGoogle Scholar
  10. 10.
    Fritsch PO, Sidoroff A: Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000, 1:349–360.PubMedCrossRefGoogle Scholar
  11. 11.
    Cribb AE, Lee B, Trepanier L, Spielberg SP: Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996, 15:9–10.PubMedGoogle Scholar
  12. 12.
    Roychowdhury S, Svensson CK: Mechanisms of drug-induced delayed type hypersensitivity reactions in the skin. AAPS J 2005, 7:E834–E846.PubMedCrossRefGoogle Scholar
  13. 13.
    Kano Y, Inaoka M, Sakuma K, Shiohara T: Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology 2005, 209:165–167.PubMedCrossRefGoogle Scholar
  14. 14.
    Hashimoto K, Yasukawa M, Tohyama M: Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 2003, 3:255–260.PubMedCrossRefGoogle Scholar
  15. 15.
    Harle DG, Baldo BA, Wells JV: Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 1988, 25:1347–1354.PubMedCrossRefGoogle Scholar
  16. 16.
    Knowles S, Shapiro L, Shear N: Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of “sulfa” allergy. Drug Saf 2001, 24:239–247.PubMedCrossRefGoogle Scholar
  17. 17.
    Carrington DM, Earl HS, Sullivan TJ: Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987, 79:442–447.PubMedCrossRefGoogle Scholar
  18. 18.
    Hansbrough JR, Wedner HJ, Chaplin DD: Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol 1987, 80:538–541.PubMedCrossRefGoogle Scholar
  19. 19.
    Verdel BM, Souverein PC, Egberts AC, Leufkens HG: Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure. Ann Pharmacother 2006, 40:1040–1046.PubMedCrossRefGoogle Scholar
  20. 20.
    Ernst EJ, Egge JA: Celecoxib-induced erythem a multiforme with glyburide cross-reactivity. Pharmacotherapy 2002, 22:637–640.PubMedCrossRefGoogle Scholar
  21. 21.
    Curtis BR, Mcfarland JG, Wu GG, et al.: Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994, 84:176–183.PubMedGoogle Scholar
  22. 22.
    Bedard K, Smith S, Cribb A: Sequential assessment of an antidrug antibody response in a patient with a systemic delayed-onset sulphonamide hypersensitivity syndrome reaction. Br J Dermatol 2000, 142:253–258.PubMedCrossRefGoogle Scholar
  23. 23.
    Gruchalla RS: Diagnosis of allergic reactions to sulfonamides. Allergy 1999, 54:28–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Friedmann PS, Lee MS, Friedmann AC, Barnetson RS: Mechanisms in cutaneous drug hypersensitivity reactions. Clin Exp Allergy 2003, 33:861–872.PubMedCrossRefGoogle Scholar
  25. 25.
    Hess DA, Sisson ME, Suria H, et al.: Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole. FASEB J 1999, 13:1688–1698.PubMedGoogle Scholar
  26. 26.
    Gruchalla RS, Pesenko RD, Do TT, Skiest DJ: Sulfonamide-induced reactions in desensitized patients with AIDS—the role of covalent protein haptenation by sulfamethoxazole. J Allergy Clin Immunol 1998, 101:371–378.PubMedCrossRefGoogle Scholar
  27. 27.
    Wulferink M, Dierkes S, Gleichmann E: Cross-sensitization to haptens: formation of common haptenic metabolites, T cell recognition of cryptic peptides, and true T cell cross-reactivity. Eur J Immunol 2002, 32:1338–1348.PubMedCrossRefGoogle Scholar
  28. 28.
    Farrell J, Naisbitt DJ, Drummond NS, et al.: Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 2003, 306:229–237.PubMedCrossRefGoogle Scholar
  29. 29.
    Schnyder B, Burkhart C, Schnyder-Frutig K, et al.: Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4 + T cells from allergic individuals. J Immunol 2000, 164:6647–6654.PubMedGoogle Scholar
  30. 30.
    Kaur C, Sarkar R, Kanwar A: Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides [letter]. Dermatology 2001, 203:351.PubMedCrossRefGoogle Scholar
  31. 31.
    Sarkar R, Kaur C, Kanwar A: Extensive fixed drug eruption to nimesulide with cross-sensitivity to sulfonamides in a child. Pediatr Dermatol 2002, 6:553–554.CrossRefGoogle Scholar
  32. 32.
    Nassif A, Bensussan A, Boumsell L, et al.: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004, 114:1209–1215.PubMedCrossRefGoogle Scholar
  33. 33.
    Johnson KK, Green DL, Rife JP, Limon L: Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother 2005, 39:290–301.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.The Ohio State UniversityColumbusUSA

Personalised recommendations